Equilibrium Dialysis and Ultrafiltration Compared for Determining the Protein Binding Rates of 99mTc-DTPA
Keywords:99mTc-DTPA, Protein Binding, Human Serum, Human Serum Albumin, Equilibrium Dialysis, Ultrafiltration.
Diethylene triaminopentaacetic acid (99mTc-DTPA) is one of the technetium radiopharmaceuticals mostly used in renal imaging for evaluation of glomera filtration rate. The 99mTc-DTPA binding rates on plasma proteins was investigated using two useful and reproducible methods. Equilibrium Dialysis (ED) and Ultrafiltration (UF) are described and there are performances compared. 99mTc-DTPA binds strongly to Human Serum (HS) than to Human Serum Albumin (HSA). In our assay, using UF technique, we found the binding rates were in HS 48.72 % ±2.58 and 51 % ±1.43 for respectively two 99mTc-DTPA concentrations [1mg/L] and [2mg/L]. Using ED method we found the binding rates were in HS 11.22 % ±2.17 and 14.94 % ±2.30 for respectively two 99m Tc-DTPA concentrations [1mg/L] and [2mg/L]. Moreover, According to HSA concentrations, the 99m Tc-DTPA binding rates increase using both techniques.
 Y. Tang, H. Zhu, Y. Zhang, and C. Huang, ‘Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography’, Biomed. Chromatogr., vol. 20, no. 10, pp. 1116–1119, Oct. 2006.
 A. Dasgupta, ‘Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management’, Clin. Chim. Acta, vol. 377, no. 1–2, pp. 1–13, Feb. 2007.
 S. Vallabhajosula, R. P. Killeen, and J. R. Osborne, ‘Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors’, Seminars in nuclear medicine, pp. 220–241, 2010.
 F. J. Klocke, ‘ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)’, Circulation, vol. 108, no. 11, pp. 1404–1418, Sep. 2003.
 M. A. L. Eriksson, J. Gabrielsson, and L. B. Nilsson, ‘Studies of drug binding to plasma proteins using a variant of equilibrium dialysis’, J. Pharm. Biomed. Anal., vol. 38, no. 3, pp. 381–389, Jul. 2005.
 H. Wan and M. Rehngren, ‘High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry’, J. Chromatogr. A, vol. 1102, no. 1–2, pp. 125–134, Jan. 2006.
 J.W. Hilson, B. Chir, R.D. Mistry, and N.M. Maisey, ‘99mTc for the measurement of glomerular filtration rate’, British Journal of Radiology, pp. 794–796, 1976.
 C. Maioli, A. Bestetti, F. Milani , G.P. Cornalba, L. Tagliabue, D.D. Benedetto et al., ‘Evaluation of different counting methods for use in radiochemical purity testing procedures for 99mTc-labelled radiopharmaceuticals’, Appl. Radiat. Isot., vol. 66, no. 4, pp. 556–559, Apr. 2008.
 ‘European Pharmacopoeia Ed 7 2011’. .
 C. .Hojelse, K. Kristensen, C.B. Sampson, ‘Factors which affectthe integrity of radiopharmaceuticals’, in Textbook of radiopharmacy, theory and practice, Gordon and Breach Science Publishers., Amsterdam: Sampson CB, editor, 1994, pp. 145–152.
 N. Vanli?-Razumeni?, J. Joksimovi?, B. Risti?, M. Tomi?, S. Beatov?, and B. Ajdinovi?, ‘Interaction of 99mTc-radiopharmaceuticals with transport proteins in human blood’, Nucl. Med. Biol., vol. 20, no. 3, pp. 363–365, 1993.
 A. E.B. Moore, S. F. Hain, G. M. Blake, and I. Fogelman, ‘Validation of Ultrafiltration as a Method of Measuring Free 99mTc-MDP’, J Nucl Med, pp. 891–897, 2003.
 M. Rehling, L.E. Nielsen and J. Marqversen, ‘Protein binding of 99mTc-DTPA compared with other GFR tracers’, Nuclear Medicine Communications, pp. 617–623, 2001.
 K.L Lee, R. Mower, T. Hollenbeck, J. Castelo, N. Johnson, P. Gordon et al., ‘Modulation of nonspecific binding in ultrafiltration protein binding studies’, Pharm. Res., vol. 20, no. 7, pp. 1015–1021, 2003.
 R. Ghosh and Z. F. Cui, ‘Fractionation of BSA and lysozyme using ultrafiltration: effect of pH and membrane pretreatment’, J. Membr. Sci., vol. 139, no. 1, pp. 17–28, 1998.
 Y. M. Huigen, T. G. Tji, W. J. Gelsema and C. L. de Ligny, ‘The Binding of 99mTc(Sn)-MDP Complexes to Human Serum Albumin and Other Blood Proteins Determined with Gel Chromatography and Ultrafiltration’, Appl. Radiat. lsot, pp. 629–635, 1989.
 B. Sebille, ‘Separation procedures used to reveal and follow drug-protein binding’, Journal of Chromatography, B: Biomedical Applications, pp. 51–77, 1990.
 M. Qiao, X. Guo, and F. Li, ‘Chemiluminescence detection coupled to high-performance frontal analysis for the determination of unbound concentrations of drugs in protein binding equilibrium’, J. Chromatogr. A, vol. 952, no. 1–2, pp. 131–138, 2002.
 C. Y. Lui and W. L. Chiou, ‘pH Shift during equilibrium dialysis’, Biopharm. Drug Dispos., vol. 7, no. 3, pp. 309–314, 1986.
 T. Trtic´-Petrovic, J.F Liu, J.A Jonsson, ‘Equilibrium sampling through membrane based on a single hollow fibre for determination of drug–protein binding and free drug concentration in plasma’, Journal of Chromatography B, pp. 169–176, 2005.
 J. Barré, J. M. Chamouard, G. Houin and J.P. Tlllement, ‘Equilibrium Dialysis, Ultrafiltration, and Ultracentrifugation Compared for Determining the Plasma-Protein-Binding Characteristics of ValproicAcid’, CLIN. CHEM., pp. 60–64, 1985.
How to Cite
Authors who submit papers with this journal agree to the following terms.